Edgestream Partners L.P. Buys Shares of 4,421 United Therapeutics Co. (NASDAQ:UTHR)

Edgestream Partners L.P. bought a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,421 shares of the biotechnology company's stock, valued at approximately $1,584,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in UTHR. Tri Locum Partners LP bought a new position in United Therapeutics during the second quarter valued at approximately $15,959,000. QRG Capital Management Inc. lifted its position in United Therapeutics by 12.4% during the second quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company's stock valued at $4,880,000 after purchasing an additional 1,692 shares during the period. Renaissance Technologies LLC lifted its position in United Therapeutics by 1.1% during the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company's stock valued at $692,748,000 after purchasing an additional 22,978 shares during the period. Vontobel Holding Ltd. lifted its position in United Therapeutics by 90.4% during the third quarter. Vontobel Holding Ltd. now owns 1,664 shares of the biotechnology company's stock valued at $596,000 after purchasing an additional 790 shares during the period. Finally, Cetera Advisors LLC purchased a new stake in United Therapeutics during the first quarter valued at approximately $475,000. Institutional investors own 94.08% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on UTHR shares. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. Argus upped their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a report on Thursday, October 31st. The Goldman Sachs Group upped their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the company a "neutral" rating in a report on Friday, November 1st. Wells Fargo & Company upped their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the company an "overweight" rating in a report on Tuesday, August 20th. Finally, HC Wainwright increased their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $370.86.

Insider Transactions at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $372.75, for a total value of $3,727,500.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at $960,576.75. This trade represents a 79.51 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christopher Causey sold 510 shares of the firm's stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the completion of the transaction, the director now directly owns 3,675 shares in the company, valued at $1,384,115.25. This represents a 12.19 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 119,442 shares of company stock worth $44,577,770. 11.90% of the stock is currently owned by insiders.

United Therapeutics Stock Performance

UTHR stock traded up $5.61 during trading on Wednesday, hitting $374.40. 151,191 shares of the company's stock traded hands, compared to its average volume of 453,867. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The business has a fifty day simple moving average of $368.28 and a 200 day simple moving average of $337.45. The stock has a market capitalization of $16.72 billion, a price-to-earnings ratio of 16.20, a P/E/G ratio of 1.08 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same quarter last year, the business earned $5.38 earnings per share. United Therapeutics's quarterly revenue was up 22.9% compared to the same quarter last year. Research analysts forecast that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.